Updates on Capsida’s Next-Generation Engineered AAV Capsids for the Clinic
Time: 2:15 pm
day: Conference Day Two
Details:
- Platform advancements leading to breakthrough, IV-delivered engineered AAV capsids for the CNS
- Generations of directed evolution yields highly targeted AAV capsids with increased therapeutic index
- Potential for Capsida’s engineered AAVs to treat neurological disorders across all age groups
